B-cell acute lymphoblastic leukemia (B-ALL) cells from patients who did not respond to CD19 CAR T-cell therapy, even though they exhibited no evidence of antigen loss, had significantly lower death receptor gene signatures than the cells from patients who had complete remission. Here, CD19 is linked to B-cell acute lymphoblastic leukemia.